---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Humanistic burden and health-related quality of life. Topics: Vision-related quality of life compared with age-matched peers: NEI VFQ-25; Driving, legal blindness registration, and loss of independence; Visual function and lesion determinants of NEI VFQ-25 scores; Change in vision-related quality of life after development of geographic atrophy; 9 further topics. 13 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Vision-related quality of life compared with age-matched peers: NEI VFQ-25

> “Vision-related functioning and QoL were poorer in patients with vs without GA (n=137 vs 52), as demonstrated by significantly lower NEI-VFQ-25 composite score (mean, 53.1 vs 84.5 points, respectively; P<0.001), as well as lower subscale scores for near activities, distance activities, dependency, driving, social functioning, mental health, role difficulties, color vision, and peripheral vision.”
> “The lower QoL observed in the GA group remained after adjusting the NEI-VFQ-25 composite score for age and sex (adjusted difference between groups, −28.82; P<0.001).”
> “Within this study conducted in the United Kingdom, Germany, Ireland, and Canada, patients with physician-confirmed diagnosis of GA secondary to AMD were recruited and interviewed prospectively.”

Source: [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

<a id="topic-2.2.1.8.1-2"></a>

### Driving, legal blindness registration, and loss of independence

> “Eighteen percent of patients with GA were either registered as legally blind according to legislation in the relevant country, or were going through the assessment process for registration (Table 3). Over half of patients with GA had a driving license (55.5%). However, half (52.0%) of these patients did not feel confident driving during the day and most (88.0%) did not feel confident driving at night.”
> “Based on the NEI-VFQ-25 questionnaire, fewer patients in the GA group were currently driving than those in the non-GA group (27.6% vs 69.2%, respectively), and among the patients who did not drive, 73.9% had given up driving in the GA group compared with only 25.0% in the non-GA group. Eyesight was reported as the most common reason for giving up driving in the GA group (80.9%).”

Source: [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

<a id="topic-2.2.1.8.1-3"></a>

### Visual function and lesion determinants of NEI VFQ-25 scores

> “The VRQoL composite score was impaired: 69.96 (24.03).”
> “In the multivariable cross-sectional analysis, predictors of the VRQoL composite score were BCVA, GA size, and low-luminance visual acuity (LLVA) for the better eye and BCVA, foveal sparing status, and LLVA for the worse eye (cross-validated R2 = 0.32).”

Source: [Künzel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7405807/)

> “The most significant associations with VRQoL scores for distance and near activities were observed in the inner lower and inner left subfields of the BE, respectively. For patients with foveal-sparing GA, the LLVA of the BE stood out as the most influential variable across all VRQoL scales.”

Source: [Künzel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12872259/)

<a id="topic-2.2.1.8.1-4"></a>

### Change in vision-related quality of life after development of geographic atrophy

> “Among AREDS participants with NEI VFQ-25 data available, 358 eyes (298 participants) developed any GA. None of the quality of life measures differed significantly pre- and post-CGA. Rasch-calibrated subscale score for visual function and composite scores declined more quickly after NCGA (difference in slope [post minus pre]: –0.10 logit/yr [95% confidence interval: –0.18, –0.01], P = 0.03; –0.78 points/yr [95% confidence interval: –1.47, –0.08], P = 0.03, respectively) and after any GA (–0.09 logit/yr [95% confidence interval: –0.16, –0.01], P = 0.02; –0.68 points/yr [95% confidence interval: –1.29, –0.07], P = 0.03, respectively).”

Source: [Prasad et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12803917/)

> “A clinically meaningful decrease in VRQOL was defined as a loss of 5 points, and the median time to significant loss of VRQOL was 4.2 years (95% CI, 3.0–5.7 years) in 259 patients,24 corresponding to a decline in 1.68 ± 4.65 NEI VFQ-25 units/year (107 patients).”

Source: [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="topic-2.2.1.8.1-5"></a>

### Visual function decline over 48 weeks in the sham-controlled Chroma and Spectri trials

> “Functional end points included change in BCVA from baseline to week 48, low-luminance visual acuity, mesopic microperimetry (number of absolute scotomatous points, mean macular sensitivity), binocular and monocular maximum reading speed, and 2 validated patient-reported outcome measures: Functional Reading Independence Index and 25-item National Eye Institute Visual Function Questionnaire.”
> “Enlargement of GA area, approximately 2 mm2/year on average across all treatment groups in each study, was accompanied by overall deterioration in all functional end points.”
> “Patients with bilateral GA experienced a consistent decline in visual function over 48 weeks, but measures of visual function were not correlated strongly with GA lesion area.”

Source: [Heier et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32199866/)

<a id="topic-2.2.1.8.1-6"></a>

### Functional reading independence

> “Qualitative interviews (n = 40) yielded a 10-item FRI Index, which was refined to seven items in quantitative testing (n = 100). Strong internal consistency (marginal reliability = 0.90) and reproducibility (intraclass correlation coefficient = 0.86) were shown.”
> “Convergent validity with binocular measures was strong (Spearman's correlation = 0.72 for reading speed, 0.66 for NEI-VFQ-25).”
> “The FRI Index demonstrated good reliability and validity in patients with GA. Further study in a broader GA population is warranted to confirm responsiveness.”

Source: [Kimel et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27893095/)

<a id="topic-2.2.1.8.1-7"></a>

### Daily activities affected: ethnographic and focus group studies

> “Sivaprasad et al25 investigated the impact of GA on daily routine activities of 16 patients with GA in Germany, the United Kingdom (UK), and the US. Patients reported difficulties with reading (100%), driving (75%), and watching television, films, or theatre (68.8%). Other concepts reported included loss of independence (56.3%) and difficulty in recognizing faces (62.5%) or performing household activities (62.5%).25”

Source: [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="topic-2.2.1.8.1-8"></a>

### Activities of daily living and NEI VFQ-39 scores: United States patient survey

> “Nearly 86% of patients (n = 88) stated that they did not currently drive.”
> “The mean (SD) driving subscale score of the NEI VFQ-39, 9.7 (20.4), was the lowest score compared with the other subscales, indicating a negative impact of GA on driving.”
> “Moderate to extreme difficulty reading a newspaper and small print (eg, medicine bottle, legal forms) was reported by 67% and 68% of patients, respectively.”
> “Losing their independence was the biggest concern reported by 56% of patients; 51% of patients worried about their eyesight most or all the time.”
> “Mean (SD) vision-specific mental health subscale score, related to the items described previously, was 46.4 (25.1).”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/)

<a id="topic-2.2.1.8.1-9"></a>

### Depression and anxiety: Medicare Advantage claims

> “In this study, the prevalence of depression at baseline was observed in one-fifth or more of the study sample (ranged 19.9%-22.6%). Furthermore, the incidence of new onset depression during the follow-up period was greater in GA cohort than non-GA cohort (86.6 vs 77.3 per 1,000 person years, P = 0.004).”
> “Additionally, approximately 20% of patients with GA in the current study had evidence of an anxiety disorder during the follow-up period”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.8.1-10"></a>

### Depression and visual performance in age-related macular degeneration

> “Results showed that 17 patients (33%) were depressed at baseline and had worse acuity (P = 0.04) and greater levels of vision-specific (P = 0.03) and general (P = 0.002) physical disability than nondepressed patients.”
> “An increase in depressive symptoms over time predicted a decline in self-reported visual function independent of changes in visual acuity or medical status (P < 0.05).33”

Source: [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="topic-2.2.1.8.1-11"></a>

### Health utility: EQ-5D index in participants with geographic atrophy

| Acceptability of injections | Participants, No. | EQ-5D health index score, median (IQR) |
| --- | --- | --- |
| Unacceptable | “27” | “0.75 (0.65 to 0.88)” |
| Acceptable | “126” | “0.74 (0.60 to 0.84)” |

Source: [Dinah et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12464851/)

> “This cross-sectional study took place at 9 geographically dispersed UK National Health Service centers from April 2023 to April 2024 among 153 participants with treatment-naive GA in at least 1 eye.”

Source: [Dinah et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12464851/)

<a id="topic-2.2.1.8.1-12"></a>

### Health utility values by visual acuity in the better-seeing eye: age-related macular degeneration overall

> “The mean utility value for the total group with age-related macular degeneration was 0.72 (95% confidence interval [CI], 0.66-0.78) using the time trade-off method and 0.81 (95% CI, 0.76-0.86) using the standard gamble method.”
> “Using the time trade-off method correlated with the visual acuity in the better-seeing eye, the results were as follow: group 1, 0.89 (95% CI, 0.82-0.96), group 2, 0.81 (95% CI, 0.73-0.89), group 3, 0.57 (95% CI, 0.47-0.67), group 4, 0.52 (95% CI, 0.38-0.66), and group 5, 0.40 (95% CI, 0.29-0.50).”

Source: [Brown et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10636413/)

<a id="topic-2.2.1.8.1-13"></a>

### Patient-reported importance of functional benefit from treatment

> “Among the 153 participants, 81 (53%; 95% CI, 45-61) reported IVCIs were very much or extremely acceptable under the theoretical scenarios provided. The proportion finding IVCIs acceptable rose to 82% (95% CI, 76-88) when including those who rated prospective treatment as moderately acceptable.”
> “While current treatments do not result in vision outcome benefits, perceived effectiveness by patients was associated with acceptability, emphasizing the desire to quantify vision functional benefit concomitant with anatomical slowing of progression.”

Source: [Dinah et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12464851/)

Additional sources: [Borkar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39571793/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
